{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Choi KH"],"funding":["Patient-centered Clinical Research Coordinating Center funded by the Ministry of Health &amp; Welfare, Republic of Korea"],"pagination":["e086971"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11367310"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(8)"],"pubmed_abstract":["<h4>Introduction</h4>There is a lack of evidence to support the effectiveness of prolonged β-blocker therapy after stabilisation of patients with acute myocardial infarction (AMI) without heart failure (HF) or left ventricular systolic dysfunction.<h4>Methods and analysis</h4>The SMart Angioplasty Research Team: DEcision on Medical Therapy in Patients with Coronary Artery DIsease or Structural Heart Disease Undergoing InterventiON (SMART-DECISION) trial is a multicentre, prospective, open-label, randomised, non-inferiority trial designed to determine whether discontinuing β-blocker therapy after ≥1 year of maintenance in stabilised patients after AMI is non-inferior to continuing it. Patients eligible for participation are those without HF or left ventricular systolic dysfunction (ejection"],"journal":["BMJ open"],"pubmed_title":["Discontinuation of β-blocker therapy in stabilised patients after acute myocardial infarction (SMART-DECISION): rationale and design of the randomised controlled trial."],"pmcid":["PMC11367310"],"funding_grant_id":["HC20C0161"],"pubmed_authors":["Her SH","Hahn JY","Yu CW","SMART-DECISION investigators","Kim J","Jeong JO","Park KT","Yoon CH","Yang JH","Park YH","Cho JH","Cho J","Kang D","Jang W","Joo SJ","Suh J","Song YB","Hwang JY","Ahn SG","Lee JM","Kim SM","Kim HK","Guallar E","Shin ES","Cho BR","Park JP","Kim BJ","Lim SH","Choi SH","Doh JH","Kim W","Gwon HC","Nam CW","Choi KH","Lee SR","Park TK"],"additional_accession":[]},"is_claimable":false,"name":"Discontinuation of β-blocker therapy in stabilised patients after acute myocardial infarction (SMART-DECISION): rationale and design of the randomised controlled trial.","description":"<h4>Introduction</h4>There is a lack of evidence to support the effectiveness of prolonged β-blocker therapy after stabilisation of patients with acute myocardial infarction (AMI) without heart failure (HF) or left ventricular systolic dysfunction.<h4>Methods and analysis</h4>The SMart Angioplasty Research Team: DEcision on Medical Therapy in Patients with Coronary Artery DIsease or Structural Heart Disease Undergoing InterventiON (SMART-DECISION) trial is a multicentre, prospective, open-label, randomised, non-inferiority trial designed to determine whether discontinuing β-blocker therapy after ≥1 year of maintenance in stabilised patients after AMI is non-inferior to continuing it. Patients eligible for participation are those without HF or left ventricular systolic dysfunction (ejection","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-07-15T08:07:22.984Z","creation":"2026-07-02T03:08:55.697Z"},"accession":"S-EPMC11367310","cross_references":{"pubmed":["39645270"],"doi":["10.1136/bmjopen-2024-086971"]}}